Witnessing the stock’s movement on the chart, on Wednesday, Cardiff Oncology Inc (NASDAQ: CRDF) set off with pace as it heaved 7.28% to $4.42, before settling in for the price of $4.12 at the close. Taking a more long-term approach, CRDF posted a 52-week range of $2.01-$5.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 19.36% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 19.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.32%. This publicly-traded company’s shares outstanding now amounts to $66.53 million, simultaneously with a float of $60.75 million. The organization now has a market capitalization sitting at $294.05 million. At the time of writing, stock’s 50-day Moving Average stood at $3.36, while the 200-day Moving Average is $3.39.
Cardiff Oncology Inc (CRDF) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Cardiff Oncology Inc’s current insider ownership accounts for 8.68%, in contrast to 42.12% institutional ownership. According to the most recent insider trade that took place on Dec 17 ’24, this organization’s Chief Financial Officer bought 2,752 shares at the rate of 5.42, making the entire transaction reach 14,905 in total value, affecting insider ownership by 65,316. Preceding that transaction, on Dec 18 ’24, Company’s Chief Financial Officer bought 2,400 for 5.00, making the whole transaction’s value amount to 12,000. This particular insider is now the holder of 67,716 in total.
Cardiff Oncology Inc (CRDF) Earnings and Revenue Records
Cardiff Oncology Inc’s EPS increase for this current 12-month fiscal period is 16.32% and is forecasted to reach -0.93 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -7.49% through the next 5 years, which can be compared against the 19.36% growth it accomplished over the previous five years trading on the market.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Let’s observe the current performance indicators for Cardiff Oncology Inc (CRDF). It’s Quick Ratio in the last reported quarter now stands at 6.22. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 498.39.
In the same vein, CRDF’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.93, a figure that is expected to reach -0.19 in the next quarter, and analysts are predicting that it will be -0.93 at the market close of one year from today.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Going through the that latest performance of [Cardiff Oncology Inc, CRDF]. Its last 5-days volume of 1.03 million was inferior to the volume of 1.18 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 88.78% While, its Average True Range was 78.87%.
Raw Stochastic average of Cardiff Oncology Inc (CRDF) in the period of the previous 100 days is set at 78.33%, which indicates a major fall in contrast to 94.44% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.23 that was lower than 0.25 volatility it exhibited in the past 100-days period.
